INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma

被引：0
|
作者：
Weber, Jeffrey S.
Luke, Jason J.
Carlino, Matteo S.
Khattak, Muhammad Adnan
Meehan, Robert S.
Brown, Michelle
Zhang, Jinchun
Krepler, Clemens
Duic, J. Paul
Long, Georgina V.
机构：
[1] NYU Langone Med Ctr, New York, NY USA
[2] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[3] Univ Sydney, Sydney Med Sch, Fac Med & Hlth Sci, Camperdown, NSW, Australia
[4] Melanoma Inst Australia, Sydney, NSW, Australia
[5] Westmead & Blacktown Hosp, Crown Princess Mary Canc Ctr, Westmead, NSW, Australia
[6] One Clin Res, Perth, WA, Australia
[7] Edith Cowan Univ, Perth, WA, Australia
[8] Moderna Inc, Cambridge, MA USA
[9] Merck & Co Inc, Rahway, NJ USA
[10] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[11] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9616
引用
收藏
页数：1
相关论文
共 40 条
  • [1] INTerpath-005: Phase II study of pembrolizumab (pembro) with V940 (mRNA-4157) versus pembro with placebo (pbo) for adjuvant treatment of resected high-risk muscle-invasive urothelial carcinoma (MIUC)
    Sonpavde, G. P.
    Perez Valderrama, B.
    Chamie, K.
    Gupta, S.
    De Santis, M.
    Meehan, R.
    Posadas, T.
    Ren, Y.
    Bavle, A.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1164 - S1164
  • [2] mRNA-4157 (V940) individualized neoantigen therapy plus pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response
    Weber, J. S.
    Khattak, A.
    Carlino, M.
    Sullivan, R. J.
    Luke, J. J.
    Meniawy, T.
    Taylor, M.
    Ansstas, G.
    Kim, K.
    Mckean, M.
    Faries, M.
    Tran, T.
    Cowey, C. L.
    Pecora, A.
    Medina, T.
    Atkinson, V. G.
    Gibney, G.
    Buchbinder, E.
    Meehan, R.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2023, 34 : S1288 - S1289
  • [3] INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma
    Jang, Albert
    Margevicius, Seunghee
    Fu, Pingfu
    Zhong, Jeffrey
    Kumar, Hamsa
    Calaway, Adam
    Shoag, Jonathan
    Bukavina, Laura
    Jia, Angela
    Mendiratta, Prateek
    Rao, Santosh
    Sheng, Iris
    Brown, Jason
    Garcia, Jorge
    Barata, Pedro
    ONCOLOGIST, 2024, 29 : S16 - S16
  • [4] INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).
    Motzer, Robert J.
    Braun, David A.
    Powles, Thomas
    Gurney, Howard
    Fong, Lawrence
    George, Daniel J.
    Haas, Naomi Balzer
    McDermott, David F.
    Shuch, Brian M.
    Meehan, Robert
    Posadas, Tracey
    Wu, Sterling
    Elfiky, Aymen
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS610 - TPS610
  • [5] KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma
    Long, Georgina V.
    Eggermont, Alexander M.
    Gershenwald, Jeffrey E.
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Dummer, Reinhard
    Hauschild, Axel
    Carlino, Matteo S.
    Ribas, Antoni
    Robert, Caroline
    Scolyer, Richard A.
    Sondak, Vernon K.
    Cohen, Jonathan E.
    Zhang, Jinchun
    Grebennik, Dmitri O.
    Krepler, Clemens
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial
    Sullivan, R. J.
    Lu, M.
    Koppolu, S.
    Weber, J. S.
    Carlino, M. S.
    Khattak, M. A.
    Ansstas, G.
    Taylor, M. H.
    Mckean, M.
    Long, G. V.
    Faries, M. B.
    Luke, J. J.
    Sehgal, V.
    Rao, A.
    Mao, H.
    Guo, J.
    Brown, M.
    Meehan, R.
    Feldman, I.
    Srinivasan, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S727 - S728
  • [7] Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
    Weber, Jeffrey S.
    Carlino, Matteo S.
    Khattak, Adnan
    Meniawy, Tarek
    Ansstas, George
    Taylor, Matthew H.
    Kim, Kevin B.
    McKean, Meredith
    Long, Georgina, V
    Sullivan, Ryan J.
    Faries, Mark
    Tran, Thuy T.
    Cowey, C. Lance
    Pecora, Andrew
    Shaheen, Montaser
    Segar, Jennifer
    Medina, Theresa
    Atkinson, Victoria
    Gibney, Geoffrey T.
    Luke, Jason J.
    Thomas, Sajeve
    Buchbinder, Elizabeth, I
    Healy, Jane A.
    Huang, Mo
    Morrissey, Manju
    Feldman, Igor
    Sehgal, Vasudha
    Robert-Tissot, Celine
    Hou, Peijie
    Zhu, Lili
    Brown, Michelle
    Aanur, Praveen
    Meehan, Robert S.
    Zaks, Tal
    LANCET, 2024, 403 (10427): : 632 - 644
  • [8] INTerpath-007: A phase II/III, adaptive, randomized study of neoadjuvant and adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) for treatment of resectable locally advanced (LA) cutaneous squamous cell carcinoma (cSCC)
    Ladwa, R.
    Davar, D.
    Lee, J.
    Silk, A. W.
    Popovtzer, A.
    Asher, N.
    Khattak, M. A.
    Meehan, R.
    Posadas, T.
    Wang, A.
    Yuan, J.
    Gross, N.
    Koyfman, S.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S652 - S653
  • [9] Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC).
    Sonpavde, Guru P.
    Valderrama, Begona P.
    Chamie, Karim
    Gupta, Shilpa
    De Santis, Maria
    Banerjee, Joydeep K.
    Ojalvo, Laureen
    Ren, Yixin
    Bavle, Abhishek
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS893 - TPS893
  • [10] Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab
    Carlino, Matteo S.
    Khattak, Adnan
    Weber, Jeffrey S.
    Meniawy, Tarek
    Sullivan, Ryan J.
    Taylor, Matthew H.
    Kim, Kevin B.
    McKean, Meredith
    Faries, Mark B.
    Cowey, Charles Lance
    Gibney, Geoffrey Thomas
    Luke, Jason J.
    Thomas, Sajeve Samuel
    Sehgal, Vasudha
    Feldman, Igor
    Aanur, Praveen
    Brown, Michelle
    Meehan, Robert S.
    Robert-Tissot, Celine
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
1234